stockportfolio.pro
Integra LifeSciences Holdings Corporation P/E Ratio 2008–2025
Integra LifeSciences Holdings Corporation (IART) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +2.6%/yr over 17 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | — | — |
| FY 2023 | 51.85 | +99.7% |
| FY 2022 | 25.96 | -23.3% |
| FY 2021 | 33.83 | -18.2% |
| FY 2020 | 41.35 | -58.8% |
| FY 2019 | 100.48 | +60.4% |
| FY 2018 | 62.64 | +7.3% |
| FY 2017 | 58.37 | +27.9% |
| FY 2016 | 45.63 | — |
| FY 2015 | — | — |
| FY 2014 | 188.59 | — |
| FY 2013 | — | — |
| FY 2012 | 48.94 | +66.8% |
| FY 2011 | 29.34 | -25.6% |
| FY 2010 | 39.42 | +2.9% |
| FY 2009 | 38.32 | +14.4% |
| FY 2008 | 33.50 | — |
Source: Integra LifeSciences Holdings Corporation SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Integra LifeSciences Holdings Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeIntegra LifeSciences Holdings Corporation — frequently asked questions
What is Integra LifeSciences Holdings Corporation's price-to-earnings ratio?
Integra LifeSciences Holdings Corporation (IART) reported price-to-earnings ratio of 51.85 for fiscal year 2023, per its SEC filings.
How has Integra LifeSciences Holdings Corporation's price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, IART's price-to-earnings ratio grew at roughly 2.6% per year (compound annual rate), from 33.50 to 51.85.
Where does this data come from?
Figures are computed from Integra LifeSciences Holdings Corporation's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.